Ruxolitinib
Phase 2RecruitingInterest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-cell Lymphoma
Conditions
T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic Leukemia, Cutaneous T Cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Trial Timeline
Feb 1, 2026 → Jan 31, 2027
NCT ID
NCT07356245About Ruxolitinib
Ruxolitinib is a phase 2 stage product being developed by Incyte for T-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07356245. Target conditions include T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell.
What happened to similar drugs?
5 of 10 similar drugs in T-cell Lymphoma were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03147742 | Pre-clinical | Completed |
| NCT04355793 | Pre-clinical | Completed |
| NCT01730755 | Pre-clinical | Completed |
| NCT05722912 | Pre-clinical | Completed |
| NCT07424222 | Phase 1 | Recruiting |
| NCT07356245 | Phase 2 | Recruiting |
| NCT07252050 | Phase 1/2 | Recruiting |
| NCT07085039 | Phase 2 | Recruiting |
| NCT05293717 | Phase 1/2 | Completed |
| NCT04908280 | Phase 2 | Completed |
| NCT04807777 | Phase 2 | Terminated |
| NCT04644211 | Phase 2 | Recruiting |
| NCT04354714 | Phase 2 | Withdrawn |
| NCT03801434 | Phase 2 | Recruiting |
| NCT03722407 | Phase 2 | Active |
| NCT03674047 | Phase 2 | Active |
| NCT03427866 | Phase 2 | Completed |
| NCT03153982 | Phase 2 | Terminated |
| NCT01895842 | Phase 1 | Completed |
| NCT01776723 | Phase 1/2 | Completed |
Competing Products
20 competing products in T-cell Lymphoma